Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Inclusion Criteria

• •1. Ambulatory male or female participants with age ≥ 50 years at the time of screening
• •2. Capable of understanding and giving written informed consent
• •3. Primary or recurrent (anti-vascular endothelial growth factor naïve) active choroidal neovascularization (CNV) lesions involving the foveal center secondary to AMD
• •4. Best corrected visual acuity (BCVA) between 20/40 and 20/200 (Snellen equivalent) in the study eye, using ETDRS testing
• •5. Willingness and ability to undertake all scheduled visits and assessments